ASCO26: Alicia Morgans, MD, MPH, ARACOG Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice. July 1, 2026 Dana-Farber Share Summary Takeaways Listen Insight Report Quiz Top Institutions 1 Dr. Alicia Morgans presented findings at #ASCO26 regarding cognitive effects of darolutamide and enzalutamide. 2 The study conducted by ARACOG indicated darolutamide resulted in less cognitive decline compared to enzalutamide. 3 Cognitive testing was utilized to assess the impact of both treatments on patients. 4 These findings may influence treatment decisions for patients requiring therapy. 5 The research was presented by Dr. Alicia Morgans from Dana-Farber Cancer Institute.
